Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs
Endpoints
Mon, 09/20/21 - 11:15 am
Tags:
Regenxbio, gene therapy, patents, Novartis, Zolgensma, SMA
Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Drugs.com
Sun, 09/19/21 - 11:58 pm
Tags:
ESMO, Novartis, clinical trials, Kisqali, breast cancer
ESMO: Novartis links prostate cancer drug to improved pain, quality of life as regulatory filings near
Fierce Biotech
Thu, 09/16/21 - 11:04 pm
Tags:
Novartis, ESMO, clinical trials, prostate cancer
First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab
Pharmaforum
Mon, 09/13/21 - 10:26 am
Tags:
Novartis, tiselizumab, FDA, esophageal cancer, BeiGene
Sandoz in oncology biosimilar deal with China’s Bio-Thera
Biopharma Reporter
Wed, 09/8/21 - 11:15 am
Tags:
Sandoz, Novartis, biosimilars, China, BAT1706, Bio-Thera Solutions
FDA grants fast track designation for Novartis’ LNA043 to treat osteoarthritis
Pharmaceutical Business Review
Fri, 09/3/21 - 11:01 am
Tags:
FDA, Novartis, osteoarthritis of the knee, LNA043
Novartis finalizes deal to make new heart drug widely available in England
BioPharma Dive
Wed, 09/1/21 - 10:55 pm
Tags:
UK, Novartis, Leqvio, heart disease, cholesterol
Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity
MedCity News
Tue, 08/31/21 - 10:05 pm
Tags:
Versanis Bio, Novartis, bimagrumab, clinical trials, funding, obesity
New fault lines emerge in CAR-T therapy
EP Vantage
Tue, 08/24/21 - 10:43 am
Tags:
CAR-T, Novartis, Kymriah, Bristol Myers Squibb, Beyanzi, Gilead Sciences, Yescarta, clinical trials
Novartis says trials back Beovu safety in diabetic eye disease
Pharmaforum
Tue, 08/17/21 - 10:08 am
Tags:
Novartis, Beovu, diabetic macular edema, Bayer, Regeneron, Eylea
WHO to study 3 drugs to treat COVID-19
Beckers Hospital Review
Thu, 08/12/21 - 11:08 am
Tags:
WHO, clinical trials, artesunate, Ipca, JNJ, infliximab, Novartis, imatinib, COVID-19
Novartis looks to manufacturing investment to drive down cost of siRNA drug
Biopharma Reporter
Mon, 08/9/21 - 11:01 am
Tags:
Novartis, Leqvio, drug manufacturing, siRNA, inclisiran
Novartis to launch new Zolgensma trial after FDA lifts restriction
Reuters
Tue, 08/3/21 - 11:01 am
Tags:
Novartis, Zolgensma, clinical trials, SMA, FDA
Drugs facing the most patent expirations this year
Drug Patent Watch
Sun, 08/1/21 - 11:46 pm
Tags:
patents, Novartis, Sunovion, Allergan, Bayer, Gilead Sciences
Novartis to pay nearly $178M in lawsuit over BRAF drug — and will be on the hook for royalty
Endpoints
Fri, 07/23/21 - 10:57 am
Tags:
Novartis, patents, Tafinlar, Plexxikon, Daiichi Sankyo
Roche takes the Tim-3 battle to Novartis
EP Vantage
Thu, 07/22/21 - 10:53 am
Tags:
Roche, sabatolimab, Novartis, RG7769, bispecific antibodies
Novartis Delivers Strong Second Quarter and 50 Million CureVac Vaccines
BioSpace
Wed, 07/21/21 - 08:39 pm
Tags:
Novartis, earnings
Novartis eyes New Year verdict from FDA on delayed Leqvio
Pharmaforum
Wed, 07/21/21 - 10:58 am
Tags:
Novartis, FDA, Leqvio, inclisiran
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report
Fierce Pharma
Thu, 07/15/21 - 12:39 pm
Tags:
Novartis, AbbVie, GSK, Roche, Eli Lilly, AstraZeneca, FDA, drug launches, drug approvals
A Chinese I/O biotech looking to turn around an old Novartis program gets a new fundraise after launching PhIII study
Endpoints
Thu, 07/15/21 - 10:46 am
Tags:
China, immuno-oncology Adlai Nortye, Novartis, funding

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.